Global Gene Therapy for Neurodegenerative Diseases Market Growth (Status and Outlook) 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global Gene Therapy for Neurodegenerative Diseases market size was valued at US$ million in 2022. With growing demand in downstream market and recovery from influence of COVID-19 and the Russia-Ukraine War, the Gene Therapy for Neurodegenerative Diseases is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during review period.
The research report highlights the growth potential of the global Gene Therapy for Neurodegenerative Diseases market. With recovery from influence of COVID-19 and the Russia-Ukraine War, Gene Therapy for Neurodegenerative Diseases are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Gene Therapy for Neurodegenerative Diseases. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Gene Therapy for Neurodegenerative Diseases market.
Key Features:
The report on Gene Therapy for Neurodegenerative Diseases market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Gene Therapy for Neurodegenerative Diseases market. It may include historical data, market segmentation by Type (e.g., Gene Replacement Therapy, Gene Silencing Therapy), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Gene Therapy for Neurodegenerative Diseases market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Gene Therapy for Neurodegenerative Diseases market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Gene Therapy for Neurodegenerative Diseases industry. This include advancements in Gene Therapy for Neurodegenerative Diseases technology, Gene Therapy for Neurodegenerative Diseases new entrants, Gene Therapy for Neurodegenerative Diseases new investment, and other innovations that are shaping the future of Gene Therapy for Neurodegenerative Diseases.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Gene Therapy for Neurodegenerative Diseases market. It includes factors influencing customer ' purchasing decisions, preferences for Gene Therapy for Neurodegenerative Diseases product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Gene Therapy for Neurodegenerative Diseases market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Gene Therapy for Neurodegenerative Diseases market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Gene Therapy for Neurodegenerative Diseases market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Gene Therapy for Neurodegenerative Diseases industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Gene Therapy for Neurodegenerative Diseases market.
Market Segmentation:
Gene Therapy for Neurodegenerative Diseases market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
According to our LPI (LP Information) latest study, the global Gene Therapy for Neurodegenerative Diseases market size was valued at US$ million in 2022. With growing demand in downstream market and recovery from influence of COVID-19 and the Russia-Ukraine War, the Gene Therapy for Neurodegenerative Diseases is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during review period.
The research report highlights the growth potential of the global Gene Therapy for Neurodegenerative Diseases market. With recovery from influence of COVID-19 and the Russia-Ukraine War, Gene Therapy for Neurodegenerative Diseases are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Gene Therapy for Neurodegenerative Diseases. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Gene Therapy for Neurodegenerative Diseases market.
Key Features:
The report on Gene Therapy for Neurodegenerative Diseases market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Gene Therapy for Neurodegenerative Diseases market. It may include historical data, market segmentation by Type (e.g., Gene Replacement Therapy, Gene Silencing Therapy), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Gene Therapy for Neurodegenerative Diseases market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Gene Therapy for Neurodegenerative Diseases market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Gene Therapy for Neurodegenerative Diseases industry. This include advancements in Gene Therapy for Neurodegenerative Diseases technology, Gene Therapy for Neurodegenerative Diseases new entrants, Gene Therapy for Neurodegenerative Diseases new investment, and other innovations that are shaping the future of Gene Therapy for Neurodegenerative Diseases.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Gene Therapy for Neurodegenerative Diseases market. It includes factors influencing customer ' purchasing decisions, preferences for Gene Therapy for Neurodegenerative Diseases product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Gene Therapy for Neurodegenerative Diseases market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Gene Therapy for Neurodegenerative Diseases market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Gene Therapy for Neurodegenerative Diseases market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Gene Therapy for Neurodegenerative Diseases industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Gene Therapy for Neurodegenerative Diseases market.
Market Segmentation:
Gene Therapy for Neurodegenerative Diseases market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
- Gene Replacement Therapy
- Gene Silencing Therapy
- Gene Editing Therapy
- Enzyme Replacement Therapy
- Hospitals and Clinics
- Research Institutions
- Biotechnology Companies
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Voyager Therapeutics
- Uniqure N.V.
- Axovant Gene Therapies
- Novartis Ag
- Amicus Therapeutics
- Regenxbio Inc.
- Sarepta Therapeutics
- Gensight Biologics
- Krystal Biotech
- Avexis
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Gene Therapy for Neurodegenerative Diseases Market Size 2018-2029
2.1.2 Gene Therapy for Neurodegenerative Diseases Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Gene Therapy for Neurodegenerative Diseases Segment by Type
2.2.1 Gene Replacement Therapy
2.2.2 Gene Silencing Therapy
2.2.3 Gene Editing Therapy
2.2.4 Enzyme Replacement Therapy
2.3 Gene Therapy for Neurodegenerative Diseases Market Size by Type
2.3.1 Gene Therapy for Neurodegenerative Diseases Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2018-2023)
2.4 Gene Therapy for Neurodegenerative Diseases Segment by Application
2.4.1 Hospitals and Clinics
2.4.2 Research Institutions
2.4.3 Biotechnology Companies
2.4.4 Others
2.5 Gene Therapy for Neurodegenerative Diseases Market Size by Application
2.5.1 Gene Therapy for Neurodegenerative Diseases Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application (2018-2023)
3 GENE THERAPY FOR NEURODEGENERATIVE DISEASES MARKET SIZE BY PLAYER
3.1 Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Players
3.1.1 Global Gene Therapy for Neurodegenerative Diseases Revenue by Players (2018-2023)
3.1.2 Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Players (2018-2023)
3.2 Global Gene Therapy for Neurodegenerative Diseases Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 GENE THERAPY FOR NEURODEGENERATIVE DISEASES BY REGIONS
4.1 Gene Therapy for Neurodegenerative Diseases Market Size by Regions (2018-2023)
4.2 Americas Gene Therapy for Neurodegenerative Diseases Market Size Growth (2018-2023)
4.3 APAC Gene Therapy for Neurodegenerative Diseases Market Size Growth (2018-2023)
4.4 Europe Gene Therapy for Neurodegenerative Diseases Market Size Growth (2018-2023)
4.5 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size Growth (2018-2023)
5 AMERICAS
5.1 Americas Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023)
5.2 Americas Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023)
5.3 Americas Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Gene Therapy for Neurodegenerative Diseases Market Size by Region (2018-2023)
6.2 APAC Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023)
6.3 APAC Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Gene Therapy for Neurodegenerative Diseases by Country (2018-2023)
7.2 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023)
7.3 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Gene Therapy for Neurodegenerative Diseases by Region (2018-2023)
8.2 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023)
8.3 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL GENE THERAPY FOR NEURODEGENERATIVE DISEASES MARKET FORECAST
10.1 Global Gene Therapy for Neurodegenerative Diseases Forecast by Regions (2024-2029)
10.1.1 Global Gene Therapy for Neurodegenerative Diseases Forecast by Regions (2024-2029)
10.1.2 Americas Gene Therapy for Neurodegenerative Diseases Forecast
10.1.3 APAC Gene Therapy for Neurodegenerative Diseases Forecast
10.1.4 Europe Gene Therapy for Neurodegenerative Diseases Forecast
10.1.5 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Forecast
10.2 Americas Gene Therapy for Neurodegenerative Diseases Forecast by Country (2024-2029)
10.2.1 United States Gene Therapy for Neurodegenerative Diseases Market Forecast
10.2.2 Canada Gene Therapy for Neurodegenerative Diseases Market Forecast
10.2.3 Mexico Gene Therapy for Neurodegenerative Diseases Market Forecast
10.2.4 Brazil Gene Therapy for Neurodegenerative Diseases Market Forecast
10.3 APAC Gene Therapy for Neurodegenerative Diseases Forecast by Region (2024-2029)
10.3.1 China Gene Therapy for Neurodegenerative Diseases Market Forecast
10.3.2 Japan Gene Therapy for Neurodegenerative Diseases Market Forecast
10.3.3 Korea Gene Therapy for Neurodegenerative Diseases Market Forecast
10.3.4 Southeast Asia Gene Therapy for Neurodegenerative Diseases Market Forecast
10.3.5 India Gene Therapy for Neurodegenerative Diseases Market Forecast
10.3.6 Australia Gene Therapy for Neurodegenerative Diseases Market Forecast
10.4 Europe Gene Therapy for Neurodegenerative Diseases Forecast by Country (2024-2029)
10.4.1 Germany Gene Therapy for Neurodegenerative Diseases Market Forecast
10.4.2 France Gene Therapy for Neurodegenerative Diseases Market Forecast
10.4.3 UK Gene Therapy for Neurodegenerative Diseases Market Forecast
10.4.4 Italy Gene Therapy for Neurodegenerative Diseases Market Forecast
10.4.5 Russia Gene Therapy for Neurodegenerative Diseases Market Forecast
10.5 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Forecast by Region (2024-2029)
10.5.1 Egypt Gene Therapy for Neurodegenerative Diseases Market Forecast
10.5.2 South Africa Gene Therapy for Neurodegenerative Diseases Market Forecast
10.5.3 Israel Gene Therapy for Neurodegenerative Diseases Market Forecast
10.5.4 Turkey Gene Therapy for Neurodegenerative Diseases Market Forecast
10.5.5 GCC Countries Gene Therapy for Neurodegenerative Diseases Market Forecast
10.6 Global Gene Therapy for Neurodegenerative Diseases Forecast by Type (2024-2029)
10.7 Global Gene Therapy for Neurodegenerative Diseases Forecast by Application (2024-2029)
11 KEY PLAYERS ANALYSIS
11.1 Voyager Therapeutics
11.1.1 Voyager Therapeutics Company Information
11.1.2 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Product Offered
11.1.3 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Voyager Therapeutics Main Business Overview
11.1.5 Voyager Therapeutics Latest Developments
11.2 Uniqure N.V.
11.2.1 Uniqure N.V. Company Information
11.2.2 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Product Offered
11.2.3 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Uniqure N.V. Main Business Overview
11.2.5 Uniqure N.V. Latest Developments
11.3 Axovant Gene Therapies
11.3.1 Axovant Gene Therapies Company Information
11.3.2 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Product Offered
11.3.3 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Axovant Gene Therapies Main Business Overview
11.3.5 Axovant Gene Therapies Latest Developments
11.4 Novartis Ag
11.4.1 Novartis Ag Company Information
11.4.2 Novartis Ag Gene Therapy for Neurodegenerative Diseases Product Offered
11.4.3 Novartis Ag Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Novartis Ag Main Business Overview
11.4.5 Novartis Ag Latest Developments
11.5 Amicus Therapeutics
11.5.1 Amicus Therapeutics Company Information
11.5.2 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Product Offered
11.5.3 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Amicus Therapeutics Main Business Overview
11.5.5 Amicus Therapeutics Latest Developments
11.6 Regenxbio Inc.
11.6.1 Regenxbio Inc. Company Information
11.6.2 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Product Offered
11.6.3 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Regenxbio Inc. Main Business Overview
11.6.5 Regenxbio Inc. Latest Developments
11.7 Sarepta Therapeutics
11.7.1 Sarepta Therapeutics Company Information
11.7.2 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Product Offered
11.7.3 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Sarepta Therapeutics Main Business Overview
11.7.5 Sarepta Therapeutics Latest Developments
11.8 Gensight Biologics
11.8.1 Gensight Biologics Company Information
11.8.2 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Product Offered
11.8.3 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Gensight Biologics Main Business Overview
11.8.5 Gensight Biologics Latest Developments
11.9 Krystal Biotech
11.9.1 Krystal Biotech Company Information
11.9.2 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Product Offered
11.9.3 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Krystal Biotech Main Business Overview
11.9.5 Krystal Biotech Latest Developments
11.10 Avexis
11.10.1 Avexis Company Information
11.10.2 Avexis Gene Therapy for Neurodegenerative Diseases Product Offered
11.10.3 Avexis Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Avexis Main Business Overview
11.10.5 Avexis Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Gene Therapy for Neurodegenerative Diseases Market Size 2018-2029
2.1.2 Gene Therapy for Neurodegenerative Diseases Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Gene Therapy for Neurodegenerative Diseases Segment by Type
2.2.1 Gene Replacement Therapy
2.2.2 Gene Silencing Therapy
2.2.3 Gene Editing Therapy
2.2.4 Enzyme Replacement Therapy
2.3 Gene Therapy for Neurodegenerative Diseases Market Size by Type
2.3.1 Gene Therapy for Neurodegenerative Diseases Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2018-2023)
2.4 Gene Therapy for Neurodegenerative Diseases Segment by Application
2.4.1 Hospitals and Clinics
2.4.2 Research Institutions
2.4.3 Biotechnology Companies
2.4.4 Others
2.5 Gene Therapy for Neurodegenerative Diseases Market Size by Application
2.5.1 Gene Therapy for Neurodegenerative Diseases Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application (2018-2023)
3 GENE THERAPY FOR NEURODEGENERATIVE DISEASES MARKET SIZE BY PLAYER
3.1 Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Players
3.1.1 Global Gene Therapy for Neurodegenerative Diseases Revenue by Players (2018-2023)
3.1.2 Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Players (2018-2023)
3.2 Global Gene Therapy for Neurodegenerative Diseases Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 GENE THERAPY FOR NEURODEGENERATIVE DISEASES BY REGIONS
4.1 Gene Therapy for Neurodegenerative Diseases Market Size by Regions (2018-2023)
4.2 Americas Gene Therapy for Neurodegenerative Diseases Market Size Growth (2018-2023)
4.3 APAC Gene Therapy for Neurodegenerative Diseases Market Size Growth (2018-2023)
4.4 Europe Gene Therapy for Neurodegenerative Diseases Market Size Growth (2018-2023)
4.5 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size Growth (2018-2023)
5 AMERICAS
5.1 Americas Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023)
5.2 Americas Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023)
5.3 Americas Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Gene Therapy for Neurodegenerative Diseases Market Size by Region (2018-2023)
6.2 APAC Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023)
6.3 APAC Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Gene Therapy for Neurodegenerative Diseases by Country (2018-2023)
7.2 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023)
7.3 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Gene Therapy for Neurodegenerative Diseases by Region (2018-2023)
8.2 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023)
8.3 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL GENE THERAPY FOR NEURODEGENERATIVE DISEASES MARKET FORECAST
10.1 Global Gene Therapy for Neurodegenerative Diseases Forecast by Regions (2024-2029)
10.1.1 Global Gene Therapy for Neurodegenerative Diseases Forecast by Regions (2024-2029)
10.1.2 Americas Gene Therapy for Neurodegenerative Diseases Forecast
10.1.3 APAC Gene Therapy for Neurodegenerative Diseases Forecast
10.1.4 Europe Gene Therapy for Neurodegenerative Diseases Forecast
10.1.5 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Forecast
10.2 Americas Gene Therapy for Neurodegenerative Diseases Forecast by Country (2024-2029)
10.2.1 United States Gene Therapy for Neurodegenerative Diseases Market Forecast
10.2.2 Canada Gene Therapy for Neurodegenerative Diseases Market Forecast
10.2.3 Mexico Gene Therapy for Neurodegenerative Diseases Market Forecast
10.2.4 Brazil Gene Therapy for Neurodegenerative Diseases Market Forecast
10.3 APAC Gene Therapy for Neurodegenerative Diseases Forecast by Region (2024-2029)
10.3.1 China Gene Therapy for Neurodegenerative Diseases Market Forecast
10.3.2 Japan Gene Therapy for Neurodegenerative Diseases Market Forecast
10.3.3 Korea Gene Therapy for Neurodegenerative Diseases Market Forecast
10.3.4 Southeast Asia Gene Therapy for Neurodegenerative Diseases Market Forecast
10.3.5 India Gene Therapy for Neurodegenerative Diseases Market Forecast
10.3.6 Australia Gene Therapy for Neurodegenerative Diseases Market Forecast
10.4 Europe Gene Therapy for Neurodegenerative Diseases Forecast by Country (2024-2029)
10.4.1 Germany Gene Therapy for Neurodegenerative Diseases Market Forecast
10.4.2 France Gene Therapy for Neurodegenerative Diseases Market Forecast
10.4.3 UK Gene Therapy for Neurodegenerative Diseases Market Forecast
10.4.4 Italy Gene Therapy for Neurodegenerative Diseases Market Forecast
10.4.5 Russia Gene Therapy for Neurodegenerative Diseases Market Forecast
10.5 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Forecast by Region (2024-2029)
10.5.1 Egypt Gene Therapy for Neurodegenerative Diseases Market Forecast
10.5.2 South Africa Gene Therapy for Neurodegenerative Diseases Market Forecast
10.5.3 Israel Gene Therapy for Neurodegenerative Diseases Market Forecast
10.5.4 Turkey Gene Therapy for Neurodegenerative Diseases Market Forecast
10.5.5 GCC Countries Gene Therapy for Neurodegenerative Diseases Market Forecast
10.6 Global Gene Therapy for Neurodegenerative Diseases Forecast by Type (2024-2029)
10.7 Global Gene Therapy for Neurodegenerative Diseases Forecast by Application (2024-2029)
11 KEY PLAYERS ANALYSIS
11.1 Voyager Therapeutics
11.1.1 Voyager Therapeutics Company Information
11.1.2 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Product Offered
11.1.3 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Voyager Therapeutics Main Business Overview
11.1.5 Voyager Therapeutics Latest Developments
11.2 Uniqure N.V.
11.2.1 Uniqure N.V. Company Information
11.2.2 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Product Offered
11.2.3 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Uniqure N.V. Main Business Overview
11.2.5 Uniqure N.V. Latest Developments
11.3 Axovant Gene Therapies
11.3.1 Axovant Gene Therapies Company Information
11.3.2 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Product Offered
11.3.3 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Axovant Gene Therapies Main Business Overview
11.3.5 Axovant Gene Therapies Latest Developments
11.4 Novartis Ag
11.4.1 Novartis Ag Company Information
11.4.2 Novartis Ag Gene Therapy for Neurodegenerative Diseases Product Offered
11.4.3 Novartis Ag Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Novartis Ag Main Business Overview
11.4.5 Novartis Ag Latest Developments
11.5 Amicus Therapeutics
11.5.1 Amicus Therapeutics Company Information
11.5.2 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Product Offered
11.5.3 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Amicus Therapeutics Main Business Overview
11.5.5 Amicus Therapeutics Latest Developments
11.6 Regenxbio Inc.
11.6.1 Regenxbio Inc. Company Information
11.6.2 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Product Offered
11.6.3 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Regenxbio Inc. Main Business Overview
11.6.5 Regenxbio Inc. Latest Developments
11.7 Sarepta Therapeutics
11.7.1 Sarepta Therapeutics Company Information
11.7.2 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Product Offered
11.7.3 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Sarepta Therapeutics Main Business Overview
11.7.5 Sarepta Therapeutics Latest Developments
11.8 Gensight Biologics
11.8.1 Gensight Biologics Company Information
11.8.2 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Product Offered
11.8.3 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Gensight Biologics Main Business Overview
11.8.5 Gensight Biologics Latest Developments
11.9 Krystal Biotech
11.9.1 Krystal Biotech Company Information
11.9.2 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Product Offered
11.9.3 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Krystal Biotech Main Business Overview
11.9.5 Krystal Biotech Latest Developments
11.10 Avexis
11.10.1 Avexis Company Information
11.10.2 Avexis Gene Therapy for Neurodegenerative Diseases Product Offered
11.10.3 Avexis Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Avexis Main Business Overview
11.10.5 Avexis Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Gene Therapy for Neurodegenerative Diseases Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
Table 2. Major Players of Gene Replacement Therapy
Table 3. Major Players of Gene Silencing Therapy
Table 4. Major Players of Gene Editing Therapy
Table 5. Major Players of Enzyme Replacement Therapy
Table 6. Gene Therapy for Neurodegenerative Diseases Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
Table 7. Global Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023) & ($ Millions)
Table 8. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2018-2023)
Table 9. Gene Therapy for Neurodegenerative Diseases Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
Table 10. Global Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023) & ($ Millions)
Table 11. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application (2018-2023)
Table 12. Global Gene Therapy for Neurodegenerative Diseases Revenue by Players (2018-2023) & ($ Millions)
Table 13. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Player (2018-2023)
Table 14. Gene Therapy for Neurodegenerative Diseases Key Players Head office and Products Offered
Table 15. Gene Therapy for Neurodegenerative Diseases Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Gene Therapy for Neurodegenerative Diseases Market Size by Regions 2018-2023 & ($ Millions)
Table 19. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Regions (2018-2023)
Table 20. Global Gene Therapy for Neurodegenerative Diseases Revenue by Country/Region (2018-2023) & ($ millions)
Table 21. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Country/Region (2018-2023)
Table 22. Americas Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023) & ($ Millions)
Table 23. Americas Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Country (2018-2023)
Table 24. Americas Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023) & ($ Millions)
Table 25. Americas Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2018-2023)
Table 26. Americas Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023) & ($ Millions)
Table 27. Americas Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application (2018-2023)
Table 28. APAC Gene Therapy for Neurodegenerative Diseases Market Size by Region (2018-2023) & ($ Millions)
Table 29. APAC Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Region (2018-2023)
Table 30. APAC Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023) & ($ Millions)
Table 31. APAC Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2018-2023)
Table 32. APAC Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023) & ($ Millions)
Table 33. APAC Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application (2018-2023)
Table 34. Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023) & ($ Millions)
Table 35. Europe Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Country (2018-2023)
Table 36. Europe Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023) & ($ Millions)
Table 37. Europe Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2018-2023)
Table 38. Europe Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023) & ($ Millions)
Table 39. Europe Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application (2018-2023)
Table 40. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Region (2018-2023) & ($ Millions)
Table 41. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Region (2018-2023)
Table 42. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023) & ($ Millions)
Table 43. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2018-2023)
Table 44. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023) & ($ Millions)
Table 45. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application (2018-2023)
Table 46. Key Market Drivers & Growth Opportunities of Gene Therapy for Neurodegenerative Diseases
Table 47. Key Market Challenges & Risks of Gene Therapy for Neurodegenerative Diseases
Table 48. Key Industry Trends of Gene Therapy for Neurodegenerative Diseases
Table 49. Global Gene Therapy for Neurodegenerative Diseases Market Size Forecast by Regions (2024-2029) & ($ Millions)
Table 50. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share Forecast by Regions (2024-2029)
Table 51. Global Gene Therapy for Neurodegenerative Diseases Market Size Forecast by Type (2024-2029) & ($ Millions)
Table 52. Global Gene Therapy for Neurodegenerative Diseases Market Size Forecast by Application (2024-2029) & ($ Millions)
Table 53. Voyager Therapeutics Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 54. Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Product Offered
Table 55. Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 56. Voyager Therapeutics Main Business
Table 57. Voyager Therapeutics Latest Developments
Table 58. Uniqure N.V. Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 59. Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Product Offered
Table 60. Uniqure N.V. Main Business
Table 61. Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 62. Uniqure N.V. Latest Developments
Table 63. Axovant Gene Therapies Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 64. Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Product Offered
Table 65. Axovant Gene Therapies Main Business
Table 66. Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 67. Axovant Gene Therapies Latest Developments
Table 68. Novartis Ag Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 69. Novartis Ag Gene Therapy for Neurodegenerative Diseases Product Offered
Table 70. Novartis Ag Main Business
Table 71. Novartis Ag Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 72. Novartis Ag Latest Developments
Table 73. Amicus Therapeutics Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 74. Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Product Offered
Table 75. Amicus Therapeutics Main Business
Table 76. Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 77. Amicus Therapeutics Latest Developments
Table 78. Regenxbio Inc. Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 79. Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Product Offered
Table 80. Regenxbio Inc. Main Business
Table 81. Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 82. Regenxbio Inc. Latest Developments
Table 83. Sarepta Therapeutics Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 84. Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Product Offered
Table 85. Sarepta Therapeutics Main Business
Table 86. Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 87. Sarepta Therapeutics Latest Developments
Table 88. Gensight Biologics Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 89. Gensight Biologics Gene Therapy for Neurodegenerative Diseases Product Offered
Table 90. Gensight Biologics Main Business
Table 91. Gensight Biologics Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 92. Gensight Biologics Latest Developments
Table 93. Krystal Biotech Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 94. Krystal Biotech Gene Therapy for Neurodegenerative Diseases Product Offered
Table 95. Krystal Biotech Main Business
Table 96. Krystal Biotech Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 97. Krystal Biotech Latest Developments
Table 98. Avexis Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 99. Avexis Gene Therapy for Neurodegenerative Diseases Product Offered
Table 100. Avexis Main Business
Table 101. Avexis Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 102. Avexis Latest Developments
Table 1. Gene Therapy for Neurodegenerative Diseases Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
Table 2. Major Players of Gene Replacement Therapy
Table 3. Major Players of Gene Silencing Therapy
Table 4. Major Players of Gene Editing Therapy
Table 5. Major Players of Enzyme Replacement Therapy
Table 6. Gene Therapy for Neurodegenerative Diseases Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
Table 7. Global Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023) & ($ Millions)
Table 8. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2018-2023)
Table 9. Gene Therapy for Neurodegenerative Diseases Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
Table 10. Global Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023) & ($ Millions)
Table 11. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application (2018-2023)
Table 12. Global Gene Therapy for Neurodegenerative Diseases Revenue by Players (2018-2023) & ($ Millions)
Table 13. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Player (2018-2023)
Table 14. Gene Therapy for Neurodegenerative Diseases Key Players Head office and Products Offered
Table 15. Gene Therapy for Neurodegenerative Diseases Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Gene Therapy for Neurodegenerative Diseases Market Size by Regions 2018-2023 & ($ Millions)
Table 19. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Regions (2018-2023)
Table 20. Global Gene Therapy for Neurodegenerative Diseases Revenue by Country/Region (2018-2023) & ($ millions)
Table 21. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Country/Region (2018-2023)
Table 22. Americas Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023) & ($ Millions)
Table 23. Americas Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Country (2018-2023)
Table 24. Americas Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023) & ($ Millions)
Table 25. Americas Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2018-2023)
Table 26. Americas Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023) & ($ Millions)
Table 27. Americas Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application (2018-2023)
Table 28. APAC Gene Therapy for Neurodegenerative Diseases Market Size by Region (2018-2023) & ($ Millions)
Table 29. APAC Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Region (2018-2023)
Table 30. APAC Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023) & ($ Millions)
Table 31. APAC Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2018-2023)
Table 32. APAC Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023) & ($ Millions)
Table 33. APAC Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application (2018-2023)
Table 34. Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023) & ($ Millions)
Table 35. Europe Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Country (2018-2023)
Table 36. Europe Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023) & ($ Millions)
Table 37. Europe Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2018-2023)
Table 38. Europe Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023) & ($ Millions)
Table 39. Europe Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application (2018-2023)
Table 40. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Region (2018-2023) & ($ Millions)
Table 41. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Region (2018-2023)
Table 42. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023) & ($ Millions)
Table 43. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2018-2023)
Table 44. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023) & ($ Millions)
Table 45. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application (2018-2023)
Table 46. Key Market Drivers & Growth Opportunities of Gene Therapy for Neurodegenerative Diseases
Table 47. Key Market Challenges & Risks of Gene Therapy for Neurodegenerative Diseases
Table 48. Key Industry Trends of Gene Therapy for Neurodegenerative Diseases
Table 49. Global Gene Therapy for Neurodegenerative Diseases Market Size Forecast by Regions (2024-2029) & ($ Millions)
Table 50. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share Forecast by Regions (2024-2029)
Table 51. Global Gene Therapy for Neurodegenerative Diseases Market Size Forecast by Type (2024-2029) & ($ Millions)
Table 52. Global Gene Therapy for Neurodegenerative Diseases Market Size Forecast by Application (2024-2029) & ($ Millions)
Table 53. Voyager Therapeutics Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 54. Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Product Offered
Table 55. Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 56. Voyager Therapeutics Main Business
Table 57. Voyager Therapeutics Latest Developments
Table 58. Uniqure N.V. Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 59. Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Product Offered
Table 60. Uniqure N.V. Main Business
Table 61. Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 62. Uniqure N.V. Latest Developments
Table 63. Axovant Gene Therapies Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 64. Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Product Offered
Table 65. Axovant Gene Therapies Main Business
Table 66. Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 67. Axovant Gene Therapies Latest Developments
Table 68. Novartis Ag Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 69. Novartis Ag Gene Therapy for Neurodegenerative Diseases Product Offered
Table 70. Novartis Ag Main Business
Table 71. Novartis Ag Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 72. Novartis Ag Latest Developments
Table 73. Amicus Therapeutics Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 74. Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Product Offered
Table 75. Amicus Therapeutics Main Business
Table 76. Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 77. Amicus Therapeutics Latest Developments
Table 78. Regenxbio Inc. Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 79. Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Product Offered
Table 80. Regenxbio Inc. Main Business
Table 81. Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 82. Regenxbio Inc. Latest Developments
Table 83. Sarepta Therapeutics Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 84. Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Product Offered
Table 85. Sarepta Therapeutics Main Business
Table 86. Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 87. Sarepta Therapeutics Latest Developments
Table 88. Gensight Biologics Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 89. Gensight Biologics Gene Therapy for Neurodegenerative Diseases Product Offered
Table 90. Gensight Biologics Main Business
Table 91. Gensight Biologics Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 92. Gensight Biologics Latest Developments
Table 93. Krystal Biotech Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 94. Krystal Biotech Gene Therapy for Neurodegenerative Diseases Product Offered
Table 95. Krystal Biotech Main Business
Table 96. Krystal Biotech Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 97. Krystal Biotech Latest Developments
Table 98. Avexis Details, Company Type, Gene Therapy for Neurodegenerative Diseases Area Served and Its Competitors
Table 99. Avexis Gene Therapy for Neurodegenerative Diseases Product Offered
Table 100. Avexis Main Business
Table 101. Avexis Gene Therapy for Neurodegenerative Diseases Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 102. Avexis Latest Developments
LIST OF FIGURES
Figure 1. Gene Therapy for Neurodegenerative Diseases Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate 2018-2029 ($ Millions)
Figure 6. Gene Therapy for Neurodegenerative Diseases Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
Figure 7. Gene Therapy for Neurodegenerative Diseases Sales Market Share by Country/Region (2022)
Figure 8. Gene Therapy for Neurodegenerative Diseases Sales Market Share by Country/Region (2018, 2022 & 2029)
Figure 9. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type in 2022
Figure 10. Gene Therapy for Neurodegenerative Diseases in Hospitals and Clinics
Figure 11. Global Gene Therapy for Neurodegenerative Diseases Market: Hospitals and Clinics (2018-2023) & ($ Millions)
Figure 12. Gene Therapy for Neurodegenerative Diseases in Research Institutions
Figure 13. Global Gene Therapy for Neurodegenerative Diseases Market: Research Institutions (2018-2023) & ($ Millions)
Figure 14. Gene Therapy for Neurodegenerative Diseases in Biotechnology Companies
Figure 15. Global Gene Therapy for Neurodegenerative Diseases Market: Biotechnology Companies (2018-2023) & ($ Millions)
Figure 16. Gene Therapy for Neurodegenerative Diseases in Others
Figure 17. Global Gene Therapy for Neurodegenerative Diseases Market: Others (2018-2023) & ($ Millions)
Figure 18. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application in 2022
Figure 19. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Player in 2022
Figure 20. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Regions (2018-2023)
Figure 21. Americas Gene Therapy for Neurodegenerative Diseases Market Size 2018-2023 ($ Millions)
Figure 22. APAC Gene Therapy for Neurodegenerative Diseases Market Size 2018-2023 ($ Millions)
Figure 23. Europe Gene Therapy for Neurodegenerative Diseases Market Size 2018-2023 ($ Millions)
Figure 24. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size 2018-2023 ($ Millions)
Figure 25. Americas Gene Therapy for Neurodegenerative Diseases Value Market Share by Country in 2022
Figure 26. United States Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 27. Canada Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 28. Mexico Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 29. Brazil Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 30. APAC Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Region in 2022
Figure 31. APAC Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type in 2022
Figure 32. APAC Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application in 2022
Figure 33. China Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 34. Japan Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 35. Korea Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 36. Southeast Asia Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 37. India Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 38. Australia Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 39. Europe Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Country in 2022
Figure 40. Europe Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2018-2023)
Figure 41. Europe Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application (2018-2023)
Figure 42. Germany Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 43. France Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 44. UK Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 45. Italy Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 46. Russia Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 47. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Region (2018-2023)
Figure 48. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2018-2023)
Figure 49. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application (2018-2023)
Figure 50. Egypt Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 51. South Africa Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 52. Israel Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 53. Turkey Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 54. GCC Country Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 55. Americas Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 56. APAC Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 57. Europe Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 58. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 59. United States Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 60. Canada Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 61. Mexico Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 62. Brazil Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 63. China Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 64. Japan Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 65. Korea Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 66. Southeast Asia Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 67. India Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 68. Australia Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 69. Germany Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 70. France Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 71. UK Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 72. Italy Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 73. Russia Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 74. Spain Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 75. Egypt Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 76. South Africa Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 77. Israel Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 78. Turkey Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 79. GCC Countries Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 80. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share Forecast by Type (2024-2029)
Figure 81. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share Forecast by Application (2024-2029)
Figure 1. Gene Therapy for Neurodegenerative Diseases Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate 2018-2029 ($ Millions)
Figure 6. Gene Therapy for Neurodegenerative Diseases Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
Figure 7. Gene Therapy for Neurodegenerative Diseases Sales Market Share by Country/Region (2022)
Figure 8. Gene Therapy for Neurodegenerative Diseases Sales Market Share by Country/Region (2018, 2022 & 2029)
Figure 9. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type in 2022
Figure 10. Gene Therapy for Neurodegenerative Diseases in Hospitals and Clinics
Figure 11. Global Gene Therapy for Neurodegenerative Diseases Market: Hospitals and Clinics (2018-2023) & ($ Millions)
Figure 12. Gene Therapy for Neurodegenerative Diseases in Research Institutions
Figure 13. Global Gene Therapy for Neurodegenerative Diseases Market: Research Institutions (2018-2023) & ($ Millions)
Figure 14. Gene Therapy for Neurodegenerative Diseases in Biotechnology Companies
Figure 15. Global Gene Therapy for Neurodegenerative Diseases Market: Biotechnology Companies (2018-2023) & ($ Millions)
Figure 16. Gene Therapy for Neurodegenerative Diseases in Others
Figure 17. Global Gene Therapy for Neurodegenerative Diseases Market: Others (2018-2023) & ($ Millions)
Figure 18. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application in 2022
Figure 19. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Player in 2022
Figure 20. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Regions (2018-2023)
Figure 21. Americas Gene Therapy for Neurodegenerative Diseases Market Size 2018-2023 ($ Millions)
Figure 22. APAC Gene Therapy for Neurodegenerative Diseases Market Size 2018-2023 ($ Millions)
Figure 23. Europe Gene Therapy for Neurodegenerative Diseases Market Size 2018-2023 ($ Millions)
Figure 24. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size 2018-2023 ($ Millions)
Figure 25. Americas Gene Therapy for Neurodegenerative Diseases Value Market Share by Country in 2022
Figure 26. United States Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 27. Canada Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 28. Mexico Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 29. Brazil Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 30. APAC Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Region in 2022
Figure 31. APAC Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type in 2022
Figure 32. APAC Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application in 2022
Figure 33. China Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 34. Japan Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 35. Korea Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 36. Southeast Asia Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 37. India Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 38. Australia Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 39. Europe Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Country in 2022
Figure 40. Europe Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2018-2023)
Figure 41. Europe Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application (2018-2023)
Figure 42. Germany Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 43. France Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 44. UK Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 45. Italy Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 46. Russia Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 47. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Region (2018-2023)
Figure 48. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2018-2023)
Figure 49. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application (2018-2023)
Figure 50. Egypt Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 51. South Africa Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 52. Israel Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 53. Turkey Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 54. GCC Country Gene Therapy for Neurodegenerative Diseases Market Size Growth 2018-2023 ($ Millions)
Figure 55. Americas Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 56. APAC Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 57. Europe Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 58. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 59. United States Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 60. Canada Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 61. Mexico Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 62. Brazil Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 63. China Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 64. Japan Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 65. Korea Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 66. Southeast Asia Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 67. India Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 68. Australia Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 69. Germany Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 70. France Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 71. UK Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 72. Italy Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 73. Russia Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 74. Spain Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 75. Egypt Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 76. South Africa Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 77. Israel Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 78. Turkey Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 79. GCC Countries Gene Therapy for Neurodegenerative Diseases Market Size 2024-2029 ($ Millions)
Figure 80. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share Forecast by Type (2024-2029)
Figure 81. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share Forecast by Application (2024-2029)
